Comparison of the stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic inflammation

Daisy C.P. Crick, Golam M. Khandaker, Sarah L. Halligan, David Burgner, Toby Mansell, Abigail Fraser

Research output: Contribution to journalReview articlepeer-review

3 Citations (SciVal)

Abstract

It has been suggested that glycoprotein acetyls (GlycA) better reflects chronic inflammation than high sensitivity C-reactive protein (hsCRP), but paediatric/life-course data are sparse. Using data from the Avon Longitudinal Study of Parents and Children (ALSPAC) and UK Biobank, we compared short- (over weeks) and long-term (over years) correlations of GlycA and hsCRP, cross-sectional correlations between GlycA and hsCRP, and associations of pro-inflammatory risk factors with GlycA and hsCRP across the life-course. GlycA showed high short-term (weeks) stability at 15 years (r = 0.75; 95% CI = 0.56, 0.94), 18 years (r = 0.74; 0.64, 0.85), 24 years (r = 0.74; 0.51, 0.98) and 48 years (r = 0.82 0.76, 0.86) and this was comparable to the short-term stability of hsCRP at 24 years. GlycA stability was moderate over the long-term, for example between 15 and 18 years r = 0.52; 0.47, 0.56 and between 15 and 24 years r = 0.37; 0.31, 0.44. These were larger than equivalent correlations of hsCRP. GlycA and concurrently measured hsCRP were moderately correlated at all ages, for example at 15 years (r = 0.44; 0.40, 0.48) and at 18 years (r = 0.55; 0.51, 0.59). We found similar associations of known proinflammatory factors and inflammatory diseases with GlycA and hsCRP. For example, BMI was positively associated with GlycA (mean difference in GlycA per standard deviation change in BMI = 0.08; 95% CI = 0.07, 0.10) and hsCRP (0.10; 0.08, 0.11). This study showed that GlycA has greater long-term stability than hsCRP, however associations of proinflammatory factors with GlycA and hsCRP were broadly similar.

Original languageEnglish
Pages (from-to)497-512
Number of pages16
JournalImmunology
Volume171
Issue number4
Early online date26 Dec 2023
DOIs
Publication statusPublished - 30 Apr 2024

Data Availability Statement


Data needed to evaluate the conclusions presented in this paper are provided in the manuscript and/or the Supplementary Materials. Additional ALSPAC data can be requested from the ALSPAC executive committee and reasonable requests from bona fide researchers will be approved. This research has been conducted using data from UK Biobank project ID: 81499, a major biomedical database and can be provided by UKB (http://www.ukbiobank.ac.uk/).

Funding

UK Biobank was generously supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the British Heart Foundation, Cancer Research UK, Department of Health, Northwest Regional Development Agency and Scottish Government. The organisation has over 150 dedicated members of staff, based in multiple locations across the UK. Golam M. Khandaker acknowledges funding support from the Wellcome Trust (grant code: 201486/Z/16/Z), the MQ: Transforming Mental Health (grant code: MQDS17/40), the Medical Research Council UK (grant code: MC_PC_17213 and MR/S037675/1) and the BMA Foundation (J Moulton grant 2019). David Burgner was supported by a National Health and Medical Research (Australia) Investigator Grant (GTN1175744). Research at the Murdoch Children's Research Institute is supported by the Victorian Government's Medical Research Operational Infrastructure research Program. This work was supported, in part, by the GW4 BIOMED DTP (Daisy C. P. Crick, MR/N0137941/), awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and DC will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website ( http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf ). This research was specifically funded by Wellcome Trust and MRC (core) (Grant ref: 76467/Z/05/Z), MRC (Grant ref: MR/L022206/1) and Wellcome Trust (Grant ref: 8426812/Z/07/Z). Toby Mansell was supported by a fellowship from Murdoch Children's Research Institute.

FundersFunder number
Department of Health, Northwest Regional Development Agency
The Wellcome Trust201486/Z/16/Z, 217065/Z/19/Z, MQDS17/40
Scottish Government
UK Research and Innovation
Royal Children's Hospital
Medical Research Council8426812/Z/07/Z, MC_PC_17213, MR/S037675/1, 76467/Z/05/Z, MR/L022206/1
British Heart Foundation
Cancer Research UK
University of Bristol
National Health and Medical Research CouncilGTN1175744
State Government of Victoria
University College London

Keywords

  • ALSPAC
  • biomarker
  • C-reactive protein
  • glycoprotein acetyls
  • inflammation
  • stability

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Comparison of the stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic inflammation'. Together they form a unique fingerprint.

Cite this